Literature Cited
Chapter 1
1 Hawkings, N., Wood, F., Butler, C. “Public Attitudes Towards Bacterial Resistance: A Qualitative Study.” Journal of Antimicrobial Chemotherapy 2007; 59:1155–1160.
2 Russell, S. “Family Still Battling Drug-Resistant Staph.” San Francisco Chronicle 2008; January 20:A–10.
3 Hersh, A., Chambers, H., Maselli, J., Gonzales, R. “National Trends in Ambulatory Visits and Antibiotic Prescribing for Skin and Soft-Tissue Infections.” Archives of Internal Medicine 2008; 168:1585–1591.
4 Klein, E., Smith, D., Laxminarayan, R. “Community-Associated Methicillin-Resistant Staphylococccus aureus in Outpatients, United States, 1999–2006.” Emerging Infectious Diseases 2009; 15:1925–1930.
5 Klein, E., Smith, D., Laxminarayan, R. “Hospitalizations and Deaths Caused by Methicillin-Resistant Staphylococcus aureus, United States, 1999–2005.” Emerging Infectious Diseases 2007; 13:1840–1846.
6 Zilberberg, M., Shorr, A., Kollef, M. “Growth and Geographic Variation in Hospitalizations with Resistant Infections, United States, 2000–2005.” Emerging Infectious Diseases 2008; 14:1756–1758.
7 Nulens, E., Broex, E., Ament, A., Deurenberg, R., Smeets, E., Scheres, J., van Tiel, F., Gordts, B., Stobberingh, E. “Cost of the Methicillin-Resistant Staphylococcus aureus Search and Destroy Policy in a Dutch University Hospital.” Journal of Hospital Infection 2008; 68:301–307.
8 Muder, R., Cunningham, C., McCray, E., Squier, C., Perreiah, P., Jain, R., Sinkowitz-Cochran, R., Jernigan, J. “Implementation of an Industrial Systems-Engineering Approach to Reduce the Incidence of Methicillin-Resistant Staphylococcus aureus Infection.” Infection Control and Hospital Epidemiology 2008; 29:702–708.
9 Woolhouse, M.E. “Where Do Emerging Pathogens Come From?” Microbe 2006; 1:511–515.
10 Woolhouse, M.E., Gowtage-Sequeria, S. “Host Range and Emerging and Reemerging Pathogens.” Emerging Infectious Diseases 2005; 11:1842–1847.
11 Turnbaugh, P., Ley, R., Mahowald, M., Magrini, V., Mardis, E., Gordon, J. “An Obesity-Associated Gut Microbiome with Increased Capacity for Energy Harvest.” Nature 2006; 444:1027–1031.
12 Amaral, F., Sachs, D., Costa, V., Fagundes, C., Cisalpino, D., Cunha, T., Ferreira, S., Cunha, F., Silva, T., Nicoli, J., Vieira, L., Souza, D., Teixeira, M. “Commensal Microbiota Is Fundamental for the Development of Inflammatory Pain.” Proceedings of the National Academy of Sciences U.S.A. 2008; 105:2193–2197.
13 Arias, C., Murray, B. “Antibiotic-Resistant Bugs in the 21st Century—a Clinical Super-Challenge.” New England Journal of Medicine 2009; 360:439–443.
14 Shlaes, D., Projan, S., Edwards, J.E. “Antibiotic Discovery: State of the State.” ASM News 2004; 70:275–281.
15 Mak J., Kim M., Pham J., Tapsall J., White P. “Antibiotic Resistance Determinants in Nosocomial Strains of Multidrug-Resistant Acinetobacter baumannii.” Journal of Antimicrobial Chemotherapy 2009; 63:47–54.
16 Park Y., Peck K., Cheong H., Chung D.-R., Song J.-H., Ko K. “Extreme Drug Resistance in Acinetobacter baumannii Infections in Intensive Care Units, South Korea.” Emerging Infectious Diseases 2009; 15:1325–1326.
17 Apisarnthanarak, A., Mundy, L. “Mortality Associated with Pandrug-Resistant Acinetobacter baumannii Infections in Thailand.” American Journal of Infection Control 2009; 37:519–520.
18 Endimiani, A., Depasquale, J., Forero, S., Perez, F., Hujer, A., Roberts-Pollack, D., Fiorella, P., Pickens, N., Kitchel, B., Casiano-Colón, A., Tenover, F., Bonomo, R. “Emergence of blaKPC-Containing Klebsiella pneumoniae in a Long-Term Acute Care Hospital: A New Challenge to our Healthcare System.” Journal of Antimicrobial Chemotherapy 2009; 64:1102–1110.
19 Hawkey, P., Jones, A. “The Changing Epidemiology of Resistance.” Journal of Antimicrobial Chemotherapy 2009; 64:Suppl 1:i3–10.
20 Gandhi, N., Moll, A., Sturm, A., Pawinski, R., Govender, T., Lalloo, U., Zeller, K., Andrews, J., Friedland, G. “Extensively Drug-Resistant Tuberculosis as a Cause of Death in Patients Co-Infected with Tuberculosis and HIV in a Rural Area of South Africa.” The Lancet 2006; 368:1575–1580.
21 Punga, V., Jakubowiak, E., Danilova, I., Somova, T., Volchenkov, G., Kazionnyy, B., Nemtsova, E., Kiryanova, E., Kourbatova, E. “Prevalence of Extensively Drug-Resistant Tuberculosis in Vladimir and Orel Regions, Russia.” International Journal of Tuberculosis and Lung Disease 2009; 13:1309–1312.
22 Tapsall, J.W. “Neisseria gonorrhoeae and Emerging Resistance to Extended Spectrum Cephalosporins.” Current Opinion in Infectious Diseases 2009; 223:87–91.
23 Matsumoto, T. “Trends of Sexually Transmitted Diseases and Antimicrobial Resistance in Neisseria gonorrhoeae.” International Journal of Antimicrobial Agents 2008; 31S:S35–S39.
24 Barry, P., Klausner, J. “The Use of Cephalosporins for Gonorrhea: The Impending Problem of Resistance.” Expert Opinion in Pharmacotherapy 2009; 10:555–577.
25 Zhu, M., Xie, Z., Zhang, L., Xia, S., Yang, W., Ran, L., Wang, Z. “Characterization of Salmonella enterica Serotype Typhimurium from Outpatients of 28 Hospitals in Henan Province in 2006.” Biomedical and Environmental Sciences 2009; 22:136–140.
26 Krauland, M., Marsh, J., Paterson, D., Harrison, L. “Integron-Mediated Multidrug Resistance in a Global Collection of Nontyphoidal Salmonella enterica Isolates.” Emerging Infectious Diseases 2009; 15:388–396.
27 Fluit, A., Wielders, C., Verhoef, J., Schmitz, F-J. “Epidemiology and Susceptibility of 3,051 Staphylococcus aureus Isolates from 25 University Hospitals Participating in the European SENTRY Study.” Journal of Clinical Microbiology 2001; 39:3727–3732.
28 Woodford, N., Livermore, D. “Infections Caused by Gram-Positive Bacteria: A Review of the Global Challenge.” Journal of Infection 2009; 59 Suppl. 1:S4–S16.
29 Pletz, M., Maus, U., Krug, N., Welte, T., Lode H. “Pneumococcal vaccines: Mechanism of Action, Impact on Epidemiology and Adaption of the Species.” International Journal of Antimicrobial Agents 2008; 32:199–206.
30 Mooi, F., van Loo, H., van Gent, M., He, Q., Bart, M., Heuveman, K., de Greeff, S., Diavaopoulos, D., Teunis, P., Nagelkerke, N., Mertsola, J. “Bordetella pertussis Strains with Increased Toxin Production Associated with Pertussis Resurgence.” Emerging Infectious Diseases 2009; 15:1206–1213.
31 Patel, S., Oshodi, A., Prasad, P., Delamora, P., Larson, E., Zaoutis, T., Paul, D., Saiman, L. “Antibiotic Use in Neonatal Intensive Care Units and Adherence with Centers for Disease Control and Prevention 12 Step Campaign to Prevent Antimicrobial Resistance.” Pediatric Infectious Disease Journal 2009; 28:1047–1051.
32 Cespedes, A., Larson, E. “Knowledge, Attitudes, and Practices Regarding Antibiotic Use Among Latinos in the United States: Review and Recommendations.” American Journal of Infection Control 2006; 34:495–502.
33 Larson, E., Dilone, J., Garcia, M., Smolowitz, J. “Factors Which Influence Latino Community Members to Self-Prescribe Antibiotics.” Nursing Research 2006; 55:94–102.
Chapter 2
34 Tyagi, S., Kramer, F. “Molecular Beacons: Probes that Fluoresce upon Hybridization.” Nature Biotechnology 1996; 14:303–308.
35 Varma-Basil, M., El-Hajj, H., Colangeli, R., Hazbón, M., Kumar, S., Bose, M., Bobadilla-del-Valle, M., García, L., Hernández, A., Kramer, F., Osornio, J., Ponce-de-León, A., Alland, D. “Rapid Detection of Rifampin Resistance in Mycobacterium tuberculosis Isolates from India and Mexico by a Molecular Beacon Assay.” Journal of Clinical Microbiology 2004; 42:5512–5516.
36 Hillemann, D., Rüsch-Gerdes, S., Richter, E. “Feasibility of the Genotype MTBDRsl Assay for Fluoroquinolone, Amikacin-Capreomycin, and Ethambutol Resistance Testing of Mycobacterium tuberculosis Strains and Clinical Specimens.” Journal of Clinical Microbiology 2009; 47:1767–1772.
37 Hillemann, D., Rüsch-Gerdes, S., Richter, E. “Evaluation of the Genotype MTBDRplus Assay for Rifampin and Isoniazid Susceptibility Testing of Mycobacterium tuberculosis Strains and Clinical Specimens.” Journal of Clinical Microbiology 2007; 45:2635–2640.
38 Cohen, J. “The Duesberg Phenomenon.” Science 1994; 266:1642–1643.
39 Abdool-Karim, S., Churchyard, G., Abdool-Karim, Q., Lawn, S. “HIV Infection and Tuberculosis in South Africa: An Urgent Need to Escalate the Public Health Response.” The Lancet 2009; 374:921–933.
40 Duesberg, P. “HIV Is Not the Cause of AIDS.” Science 1988; 241:514.
41 Duesberg, P., Koehnlein, C., Rasnick, D. “The Chemical Bases of the Various AIDS Epidemics: Recreational Drugs, Anti-Viral Chemotherapy and Malnutrition.” Journal of Biosciences 2003; 28:383–412.
42 Cohen, J. “Could Drugs, Rather Than a Virus, Be the Cause of AIDS?” Science 1994; 266:1648–1649.
43 Cohen, J. “Fulfilling Koch’s Postulates.” Science 1994; 266.
44 Anonymous. “Blattner and Colleagues Respond to Duesberg.” Science 1988; 241:514–517.
45 Blattner, W., Gallo, R., Temin, H. “HIV Causes AIDS.” Science 1988; 241:515.
46 Cohen, J. “Duesberg and Critics Agree: Hemophilia Is the Best Test.” Science 1994; 266:1645–1646.
47 Cohen, J. “The Epidemic in Thailand.” Science 1994; 266:1647.
48 Moore, J. “A Duesberg, adieu!” Nature 1996; 380:293–294.
49 Chêne, G., Sterne, J., May, M., Costagliola, D., Ledergerber, B., Phillips, A., Dabis, F., Lundgren, J., Monforte, A., de-Wolf, F., Hogg, R., Reiss, P., Justice, A., Leport, C., Staszewski, S., Gill, J., Fatkenheuer, G., Egger, M. “Prognostic Importance of Initial Response in HIV-1 Infected Patients Starting Potent Antiretroviral Therapy: Analysis of Prospective Studies.” The Lancet 2003; 362:679–686.
50 Espinosa, J., Herva, M., Andréoletti, O., Padilla, D., Lacroux, C., Cassard, H., Lantier, I., Castilla, J., Torres, J. “Transgenic Mice Expressing Porcine Prion Protein Resistant to Classical Scrapie but Susceptible to Sheep Bovine Spongiform Encephalopathy and Atypical Scrapie.” Emerging Infectious Diseases 2009; 15:1214–1221.
51 Falkow, S. “Molecular Koch’s Postulates Applied to Microbial Pathogenicity.” Reviews of Infectious Diseases 1988; 10 Suppl 2:S274–S276.
52 Kiran, M., Giacomett, A., Cirioni, O., Balaban, N. “Suppression of Biofilm Related, Device-Associated Infections by staphylococcal Quorum Sensing Inhibitors.” International Journal of Artificial Organs 2008; 31:761–770.
Chapter 3
53 Dixon, B. “Sulfa’s True Significance.” Microbe 2006; 1:500–501.
54 Alekshun, M., Levy, S. “Molecular Mechanisms of Antibacterial Multidrug Resistance.” Cell 2007; 128:1037–1050.
55 Shah, N., Alker, A., Sem, R., Susanti, A., Muth, S., Maguire, J., Duong, S., Ariey, F., Meshnick, S., Wongsrichanalai, C. “Molecular Surveillance for Multidrug-Resistant Plasmodium falciparum, Cambodia.” Emerging Infectious Diseases 2008; 14:1637–1640.
56 Farmer, T., Gilbart, J., Elson, S. “Biochemical Basis of Mupirocin Resistance in Strains of Staphylococcus aureus.” Journal of Antimicrobial Chemotherapy 1992; 30:587–596.
57 O’Neill, A., Chopra, I. “Molecular Basis of fusB-Mediated Resistance to Fusidic Acid in Staphylococcus aureus.” Molecular Microbiology 2006; 59:664–676.
58 Sidhu, A., Verdier-Pinard, D., Fidock, D.A. “Chloroquine Resistance in Plasmodium falciparum Malaria Parasites Conferred by pfcrt mutations.” Science 2002; 298:210–213.
59 Ernst, C., Staubitz, P., Mishra, N., Yang, S., Hornig, G., Kalbacher, H., Bayer, A., Kraus, D., Peschel, A. “The Bacterial Defensin Resistance Protein MprF Consists of Separable Domains for Lipid Lysinylation and Antimicrobial Peptide Repulsion.” PLoS Pathogens 2009; 5:e1000660.
60 Jhingran, A., Chawla, B., Saxena, S., Barrett, M., Madhubala, R. “Paromomycin: Uptake and Resistance in Leishmania donovani.” Molecular and Biochemical Parasitology 2009; 164:111–117.
61 Duan, R., de Vries, R., van Dun, J., van Loenen, F., Osterhaus, A., Remeijer, L., Verjans, G. “Acyclovir Susceptibility and Genetic Characteristics of Sequential Herpes Simplex Virus Type 1 Corneal Isolates from Patients with Recurrent Herpetic Keratitis.” Journal of Infectious Diseases 2009; 200:1402–1414.
62 Geerts, S., Gryseels, B. “Drug Resistance in Human Helminths: Current Situation and Lessons from Livestock.” Clinical Microbiology Reviews 2000; 13:207–222.
63 Favre, B., Ghannoum, M., Ryder, N. “Biochemical Characterization of Terbinafine-Resistant Trichophyton rubrum Isolates.” Medical Mycology 2004; 42:525–529.
64 Nielsen-Kahn, J., Garcia-Effron, G., Hsu, M.-J., Park, S., Marr, K.A., Perlin, D.S. “Acquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan Synthase.” Antimicrobial Agents and Chemotherapy 2007; 51:1876–1878.
65 Papon, N., Noël T., Florent M., Gibot-Leclerc, S., Jean, D., Chastin, C., Villard, J., Chapeland-Leclerc, F. “Molecular Mechanism of Flucytosine Resistance in Candida lusitaniae: Contribution of the FCY2, FCY1, and FUR1 Genes to 5-fluorouracil and Fluconazole Cross-Resistance.” Antimicrobial Agents and Chemotherapy 2007; 51:369–371.
66 Paredes, R., Clotet, B. “Clinical Management of HIV-1 Resistance.” Antiviral Research 2010; 85:245-265.
67 Perichon, B., Courvalin, P. “VanA-type Vancomycin-Resistant Staphylococcus aureus.” Antimicrobial Agents and Chemotherapy 2009; 53:4580–4587.
68 Finks, J., Wells, E., Dyke, T., Husain, N., Plizga, L., Heddurshetti, R., Wilkins, M., Rudrik, J., Hageman, J., Patel, J., Miller, C. “Vancomycin-Resistant Staphylococcus aureus, Michigan, USA, 2007.” Emerging Infectious Diseases 2009; 15:943–945.
69 Anonymous. Sulfonamide (Medicine): Wikipedia, 2008.
70 Anonymous. U.S. Food and Drug Administration: Wikipedia, 2008.
71 Dwyer, D., Kohanski, M., Hayete, B., Collins, J. “Gyrase Inhibitors Induce an Oxidative Damage Cellular Death Pathway in Escherichia coli.” Molecular and Systems Biology 2007; 3:91. Epub.
72 Kohanski, M., Dwyer, D., Hayete, B., Lawrence, C., Collins, J. “A Common Mechanism of Cellular Death Induced by Bactericidal Antibiotics.” Cell 2007; 130:797–810.
73 Wang, X., Zhao, X. “Contribution of Oxidative Damage to Antimicrobial Lethality.” Antimicrobial Agents and Chemotherapy 2009; 53:1395–1402.
74 MacKenzie, W., Hoxie, N., Proctor, M., Gradus, M., Blair, K., Peterson, D., Kazmierczak, J., Addiss, D., Fox, K., Rose, J., Davis, J. “A Massive Outbreak in Milwaukee of Cryptosporidium Infection Transmitted Through the Public Water Supply.” New England Journal of Medicine 1994; 331:161–167.
75 Acar, J., Goldstein, F. “Trends in Bacterial Resistance to Fluoroquinolones.” Clinical Infectious Diseases 1997; 24:S67–S73.
76 Chen, D.K., McGeer, A., deAzavedo J.C., Low, D.E. “Decreased Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada.” New England Journal of Medicine 1999; 341:233–239.
77 Park-Wyllie, L., Juurlink, D., Kopp, A., Shah, B., Stukel, T., Stumpo, C., Dresser, L., Low, D., Mamdani, M. “Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults.” New England Journal of Medicine 2006; 354:1352–1361.
78 von Gottberg, A., Klugman, K., Cohen, C., Wolter, N., de Gouveia, L., du Plessis, M., Mpembe, R., Quan, V., Whitelaw, A., Hoffmann, R., Govender, N., Meiring, S., Smith, A., Schrag, S. “Emergence of Levofloxacin-Non-Susceptible Streptococcus pneumoniae and Treatment for Multidrug-Resistant Tuberculosis in Children in South Africa: A Cohort Observational Surveillance Study.” The Lancet 2008; 371:1108–1113.
79 Perlman, D., ElSadr, W., Heifets, L., Nelson, E., Matts, J., Chirgwin, K., Salomon, N., Telzak, E., Klein, O., Kreiswirth, B., Musser, J., Hafner, R. “Susceptibility to Levofloxacin of Mycobacterium tuberculosis Isolates from Patients with HIV-Related Tuberculosis and Characterization of a Strain with Levofloxacin Monoresistance.” AIDS 1997; 11:1473–1478.
80 Drlica, K., Zhao, X., Kreiswirth, B. “Minimizing Moxifloxacin Resistance with Tuberculosis.” Lancet Infectious Diseases 2008; 8:273–275.
81 German, N., Malik, M., Rosen, J., Drlica, K., Kerns, R. “Use of Gyrase Resistance Mutants to Guide Selection of 8-Methoxy-Quinazoline-2,4-Diones.” Antimicrobial Agents and Chemotherapy 2008; 52:3915–3921.
82 Malik, M., Hoatam, G., Chavda, K., Kerns, R., Drlica. K. “Novel Approach for Comparing Quinolones for Emergence of Resistant Mutants During Quinolone Exposure.” Antimicrobial Agents and Chemotherapy 2010; 54:149–156.
Chapter 4
83 Ley, R., Hamady, M., Lozupone, C., Turnbaugh, P., Ramey, R., Bircher, J., Schlegel, M., Tucker, T., Schrenzel, M., Knight, R., Gordon, J. “Evolution of Mammals and Their Gut Microbes.” Science 2008; 320:1647–1651.
84 Kahlmeter, G., Brown, D. “Harmonization of Antimicrobial Breakpoints in Europe—Can It Be Achieved?” Clinical Microbiology Newsletter 2004; 26:187–192.
85 David, M., Crawford, S., Boyle-Vavra, S., Hostetler, M., Kim, D., Daum, R. “Contrasting Pediatric and Adult Methicillin-Resistant Isolates.” Emerging Infectious Diseases 2006; 12:631–637.
86 Shin, S., Yagui, M., Ascencios, L., Yale, G., Suarez, C., Quispe, N., Bonilla, C., Blaya, J., Taylor, A., Contreras, C., Cegielski, P., “Scale-Up of Multidrug-Resistant Tuberculosis Laboratory Services, Peru.” Emerging Infectious Diseases 2008; 14:701–708.
87 Bonilla, C., Crossa, A., Jave, H., Mitnick, C., Jamanca, R., Herrera, C., Asencios, L., Mendoza, A., Bayona, J., Zignol, M., Jaramillo, E. “Management of Extensively Drug-Resistant Tuberculosis in Peru: Cure Is Possible.” PLos ONE 2008; 3:e2957.
88 Gumbo, T., Louie, A., Deziel, M., Parsons, L., Salfinger, M., Drusano, G. “Selection of a Moxifloxacin Dose That Suppresses Drug Resistance in Mycobacterium tuberculosis by Use of an In Vitro Pharmacodynamic Infection Model and Mathematical Modeling.” Journal of Infectious Diseases 2004; 190:1642–1651.
89 Craig, W.A. “Pharmacodynamics of Antimicrobials: General Concepts and Applications.” In: Nightingale, C., Murakawa, T., Ambrose, P, eds. Antimicrobial Pharmacodynamics in Theory and Clinical Practice New York: Marcel Dekker, 2002:1–22.
90 Craig, W.A., Andes, D.R. “Correlation of the Magnitude of the AUC24/MIC for 6 Fluoroquinolones Against Streptococcus pneumoniae (SP) with Survival and Bactericidal Activity in an Animal Model,” 40th ICAAC, 2000.
91 Menson, E., Walker, A., Sharland, M., Wells, C., Tudor-Williams, G., Riordan, F., Lyall, E., Gibb, D., and The Collaborative-HIV-Paediatric-Study-Steering-Committee. “Underdosing of Antiretrovirals in UK and Irish Children with HIV as an Example of Problems in Prescribing Medicines to Children, 1997–2005: Cohort Study.” British Medical Journal 2006; 332:1183–1187.
92 Lehrnbecher, T., Kaiser, J., Varwig, D., Ritter, J., Groll, A., Creutzig, U., Klingebiel, T., Schwabe, D. “Antifungal Usage in Children Undergoing Intensive Treatment for Acute Myeloid Leukemia: Analysis of the Multicenter Clinical Trial AML-BFM 93.” European Journal of Clinical Microbiology and Infectious Diseases 2007; 26:735–738.
93 Paci, P., Carello, R., Bernaschi, M., D’Offizi, G., Castiglione, F. “Immune Control of HIV-1 Infection After Therapy Interruption: Immediate versus Deferred Antiretroviral Therapy.” BMC Infectious Diseases 2009; 9:172.
94 World-Health-Organization. “Anti-Tuberculosis Drug Resistance in the World.” Report No. 4. Geneva, 2008:WHO/HTB/TB/2008.394.
95 Bergval, I., Schuitema, A., Klatser, P., Anthony, R. “Resistant Mutants of Mycobacterium tuberculosis Selected In Vitro Do Not Reflect the In Vivo Mechanism of Isoniazid Resistance.” Journal of Antimicrobial Chemotherapy 2009; 64:515–523.
96 Stronati, M., Borghesi, A., Decembrino, L., Bollani, L. “Antibiotics in Neonatal Intensive Care Units (NICUs).” Journal of Antimicrobial Chemotherapy 2007; Suppl 2:52–55.
97 Grigoryan, L., Haaijer-Rysjamp, F., Burgerhof, J., Mechtler, R., Deschepper, R., Tambic-Andrasevic, A,, Andrajati, R., Monnet, D., Cunney, R., DiMatteo, A., Edelsein, H., Valinteliene, R., Alkerwi, A., Scicluna, E., Grzesiowski, P., Bara, A., Tesar, T., Cizman, M., Campos, J., Lundborg, C., Birkin, J. “Self-Medication with Antimicrobial Drugs in Europe.” Emerging Infectious Diseases 2006; 12:452–459.
98 McNulty, C., Boyle, P., Nichols, T., Clappison, D., Davey, P. “Antimicrobial Drugs in the Home, United Kingdom.” Emerging Infectious Diseases 2006; 12:1523–1526.
99 Mainous, A., Cheng, A., Garr R., Tilley, B., Everett, C., McKee M. “Nonprescribed Antimicrobial Drugs in Latino Community, South Carolina.” Emerging Infectious Diseases 2005; 11:883–888.
100 Cespedes, A., Larson, E. “Knowledge, Attitudes, and Practices Regarding Antibiotic Use Among Latinos in the United States: Review and Recommendations.” American Journal of Infection Control 2006; 34:495–502.
101 Larson, E., Dilone, J., Garcia, M., Smolowitz, J. “Factors Which Influence Latino Community Members to self-prescribe Antibiotics.” Nursing Research 2006; 55:94–102.
102 Andes, D., Craig, W. “Pharmacodynamics of the New Fluoroquinolone Gatifloxacin in Murine Thigh and Lung Infection Models.” Antimicrobial Agents and Chemotherapy 2002; 46:1665–1670.
Chapter 5
103 Sieradzki, K., Leski, T., Dick, J., Borio, L., Tomasz, A. “Evolution of a Vancomycin-Intermediate Staphylococcus aureus Strain In Vivo: Multiple Changes in the Antibiotic Resistance Phenotypes of a Single Lineage of Methicillin-Resistant S. aureus Under the Impact of Antibiotics Administered for Chemotherapy.” Journal of Clinical Microbiology 2003; 41:1687–1693.
104 Davidson, R., Cavalcanti, R., Brunton, J., Bast, D., deAzavedo, J., Kibsey, P., Fleming, C., Low, D. “Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia.” New England Journal of Medicine 2002; 346:747–750.
105 Cui, J., Liu, Y., Wang, R., Tong, W., Drlica, K., Zhao, X. “The Mutant Selection Window Demonstrated in Rabbits Infected with Staphylococcus aureus.” Journal of Infectious Diseases 2006; 194:1601–1608.
106 Bridges, B. “Hypermutation in Bacteria and Other Cellular Systems.” Philosophical Transactions of the Royal Society London B Biological Science 2001; 356:29–39.
107 Urban, C., Rahman, N., Zhao, X., Mariano, N., Segal-Maurer, S., Drlica, K., Rahal, J. “Fluoroquinolone-Resistant Streptococcus pneumoniae Associated with Levofloxacin Therapy.” Journal of Infectious Diseases 2001; 184:794–798.
108 Liu, Y., Cui, J., Wang, R., Wang, X., Drlica, K., Zhao, X. “Selection of Rifampicin–Resistant Staphylococcus aureus During tuberculosis Therapy: Concurrent Bacterial Eradication and Acquisition of Resistance.” Journal of Antimicrobial Chemotherapy 2005; 56:1172–1175.
109 Zhao, X., Drlica, K. “Restricting the Selection of Antibiotic-Resistant Mutants: a General Strategy Derived from Fluoroquinolone Studies.” Clinical Infectious Diseases 2001; 33 (Suppl 3):S147–S156.
110 Drlica, K., Zhao, X. “Mutant Selection Window Hypothesis Updated.” Clinical Infectious Diseases 2007; 44:681–688.
111 Zhou, J., Dong, Y., Zhao, X., Lee, S., Amin, A., Ramaswamy, S., Domagala, J., Musser, J., Drlica, K. “Selection of Antibiotic Resistant Bacterial Mutants: Allelic Diversity Among Fluoroquinolone-Resistant Mutations.” Journal of Infectious Diseases 2000; 182:517–525.
112 Blondeau, J., Zhao, X., Hansen, G., Drlica, K. “Mutant Prevention Concentrations (MPC) for Fluoroquinolones with Clinical Isolates of Streptococcus pneumoniae.” Antimicrobial Agents and Chemotherapy 2001; 45:433–438.
113 Quinn, B., Hussain, S., Malik, M., Drlica, K., Zhao, X. “Daptomycin Inoculum Effects and Mutant Prevention Concentration with Staphylococcus aureus.” Journal of Antimicrobial Chemotherapy 2007; 60:1380–1383.
114 Firsov, A., Vostrov, S., Lubenko, I., Drlica, K., Portnoy, Y., Zinner, S. “In Vitro Pharmacodynamic Evaluation of the Mutant Selection Window Hypothesis: Four Fluoroquinolones Against Staphylococcus aureus.” Antimicrobial Agents and Chemotherapy 2003; 47:1604–1613.
115 Zinner, S., Lubenko, I., Gilbert, D., Simmons, K., Zhao, X., Drlica, K., Firsov, A. “Emergence of Resistant Streptococcus pneumoniae in an In Vitro Dynamic Model That Simulates Moxifloxacin Concentration In and Out of the Mutant Selection Window: Related Changes in Susceptibility, Resistance Frequency, and Bacterial Killing.” Journal of Antimicrobial Chemotherapy 2003; 52:616–622.
116 Cirz, R., Chin, J., Andes, D., Crecy-Lagard, V., Craig, W., Romesberg, F.E. “Inhibition of Mutation and Combating the Evolution of Antibiotic Resistance.” Plos Biology 2005; 3:1024–1033.
117 Cirz, R., Romesberg, F. “Induction and Inhibition of Ciprofloxacin Resistance-Conferring Mutations in Hypermutator Bacteria.” Antimicrobial Agents and Chemotherapy 2006; 50:220–225.
118 Poole, K. “Efflux-Mediated Antimicrobial Resistance.” Journal of Antimicrobial Chemotherapy 2005; 56:20–51.
119 Fraud, S., Campigotto, A., Chen, Z., Poole, K. “The MexCD-OprJ Multidrug Efflux System of Pseudomonas aeruginosa: Involvement in Chlorhexidine Resistance and Induction by Membrane Damaging Agents Dependent Upon the AlgU Stress-Response Sigma Factor.” Antimicrobial Agents and Chemotherapy 2008; 52:4478–4482.
120 Jeannot, K., Elsen, S., Köhler, T., Attree, I., van Delden, C., Plésiat, P. “Resistance and Virulence of Pseudomonas aeruginosa Clinical Strains Overproducing the MexCD-OprJ Efflux Pump.” Antimicrobial Agents and Chemotherapy 2008; 52:2455–2462.
121 Rice, L. “Evolution and Clinical Importance of Extended-Spectrum β-Lactamases.” Chest 2001; 119:391–396.
122 Datta, N., Kontomichalou, P. “Penicillinase Synthesis Controlled by Infectious R Factors in Enterobacteriaceae.” Nature 1965; 208:239–241.
123 Saudagar, P., Survase, S., Singhal, R. “Clavulanic Acid: a Review.” Biotechnology Advances 2008; 26:335–351.
124 Song, S., Berg, O., Roth, J., Andersson, D. “Contribution of Gene Amplification to Evolution of increased Antibiotic Resistance in Salmonella typhimurium.” Genetics 2009; 182:1183–1195.
125 Hegde, S., Vetting, M., Roderick, S., Mitchenall, L., Maxwell, A., Takiff, H., Blanchard, J. “A Fluoroquinolone Resistance Protein from Mycobacterium tuberculosis That Mimics DNA.” Science 2005; 308:1480–1483.
126 Miller, J. “Spontaneous Mutators in Bacteria: Insights into Pathways of Mutagenesis and Repair.” Annual Review of Microbiology 1996; 50:625–643.
127 Oliver, A., Levin, B., Juan, C., Baquero, F., Blazquez, J. ““Hypermutation and the Preexistence of Antibiotic-Resistant Pseudomonas aeruginosa Mutants: Implications for Susceptibility Testing and Treatment of Chronic Infections. Antimicrobial Agents and Chemotherapy 2004; 48:4226–4233.
128 Rhee, K., Sethupathi, P., Driks, A., Lanning, D., Knight, K. “Role of Commensal Bacteria in Development of Gut-Associated Lymphoid Tissues and Preimmune Antibody Repertoire.” Journal of Immunology 2004; 172:1118–1124.
129 Poole, K. “Efflux-Mediated Antimicrobial Resistance.” Journal of Antimicrobial Chemotherapy 2005; 56:20–51.
130 Domingo, A., Holland, J. “RNA Virus Mutations and Fitness for Survival.” Annual Review of Microbiology 1997; 51:151–178.
131 Metzner, K., Giulieri, S., Knoepfel, S., Rauch, P., Burgisser, P., Yerly, S., Günthard, H., Cavassini, M. “Minority Quasispecies of Drug-Resistant HIV-1 That Lead to Early Therapy Failure in Treatment-Naive and -Adherent Patients.” Journal of Clinical Microbiology 2009; 48:239–247.
132 Le, T., Chiarella, J., Simen, B., Hanczaruk, B., Egholm, M., Landry,M., Dieckhaus, K., Rosen, M., Kozal, M. “Low-Abundance HIV Drug-Resistant Viral Variants in Treatment-Experienced Persons Correlate with Historical Antiretroviral Use.” PLoS ONE 2009; 4:e6078.
133 Little, S., Frost, S., Wong, J., Smith, D., Pond, S., Ignacio, C., Parkin, N., Petropoulos, C., Richman, D. “Persistence of Transmitted Drug Resistance Among Subjects with Primary Human Immunodeficiency Virus Infection.” Journal of Virology 2008; 82:5510–5518.
134 Ross, L., Lim, M., Liao, Q., Wine, B., Rodriguez, A., Weinberg, W., Shaefer, M. “Prevalence of Antiretroviral Drug Resistance and Resistance-Associated Mutations in Antiretroviral Therapy-Naïve HIV Infected Individuals from 40 United States Cities.” HIV Clinical Trials 2007; 8:1–8.
135 Aarestrup, F.M. “Monitoring of Antimicrobial Resistance Among Food Animals: Principles and Limitations.” Journal of Veterinary Medicine 2004; B51:380–388.
136 Songer, J., Trinh, H., Killgore, G., Thompson, A., McDonald, L., Limbago, B. “Clostridium difficile in Retail Meat Products, USA, 2007.” Emerging Infectious Diseases 2009; 15:819–821.
137 Rodriguez-Palacios, A., Reid-Smith, R., Staempfli, H., Daignault, D., Janecko, N., Avery, B., Martin, H., Thomspon, A., McDonald, L., Limbago, B., Weese, J. “Possible Seasonality of Clostridium difficile in Retail Meat, Canada.” Emerging Infectious Diseases 2009; 15:802–805.
138 Bakri, M., Brown, D., Butcher, J., Sutherland, A. “Clostridium difficile in Ready-to-Eat Salads, Scotland.” Emerging Infectious Diseases 2009; 15:817–818.
139 Zilberberg, M., Shorr, A., Kollef, M. “Increase in Adult Clostridium difficile-Related Hospitalizations and Case-Fatality Rate, United States, 2000–2005.” Emerging Infectious Diseases 2008; 14:929–931.
140 Jagal, J., Naumova E. “Clostridium difficile-Associated Disease in the Elderly, United States.” Emerging Infectious Diseases 2009; 15:343–344.
141 McDonald, L., Owings, M., Jernigan, D. “Clostridium difficile Infection in Patients Discharged from US Short-Stay Hospitals, 1996–2003.” Emerging Infectious Diseases 2006; 12:409–415.
142 Bartlett, J., Gerding, D. “Clinical Recognition and Diagnosis of Clostridium difficle Infection.” Clinical Infectious Disease 2008; 46:S12–S18.
143 O’Brien, J., Lahue, B., Caro, J., Davidson, D. “The Emerging Infectious Challenge of Clostridium difficile-Associated Disease in Massachusetts Hospitals: Clinical and Economic Consequences.” Infection Control and Hospital Epidemiology 2007; 28:1219–1227.
144 Davidson, R., Davis, I., Willey, B., Rizg, K., Bolotin, S., Porter, V., Polsky, J., Daneman, N., McGeer, A., Yang, P., Scolnik, D., Rowsell, R., Imas, O., Silverman, M. “Antimalarial Therapy Selection for Quinolone Resistance Among Escherichia coli in the Absence of Quinolone Exposure in Tropical South America.” PLoS ONE 2008; 3:e2727.
Chapter 6
145 Chhibber, S., Kaur, S., Kumari, S. “Therapeutic Potential of Bacteriophage in Treating Klebsiella pneumoniae B5055-Mediated Lobar Pneumonia in Mice.” Journal of Medical Microbiology 2008; 57:1508–1513.
146 Garau, J., Xercavins, M., Rodriguez-Carballerira, M., Gomez-Vera, J., Coll, I., Vidal, D., Llovet, T., Ruiz-Bremon, A. “Emergence and Dissemination of Quinolone-Resistant Escherichia coli in the Community.” Antimicrobial Agents and Chemotherapy 1999; 43:2736–2741.
147 Fantin, B., Duval, X., Massias, L., Alavoine, L., Chau, F., Retout, S., Andremont, A., Mentré, F. “Ciprofloxacin Dosage and Emergence of Resistance in Human Commensal Bacteria.” Journal of Infectious Diseases 2009; 200:390–398.
148 Bartoloni, A., Pallecchi, L., Fiorelli, C., DiMaggio, T., Fernandez, C., Villagran, A., Mantella, A., Bartalesi, F., Strohmeyer, M., Bechini, A., Gamboa, H., Rodriguez, H., Kristiansson, C., Kronvall, G., Gotuzzo, E., Paradisi, F., Rossolini, G. “Increasing Resistance in Commensal Escherichia coli, Bolivia and Peru.” Emerging Infectious Diseases 2008; 14:338–340.
149 Mazel, D. “Integrons: Agents of Bacterial Evolution.” Nature Reviews in Microbiology 2006; 4:608–620.
150 Márquez, C., Labbate, M., Raymondo, C., Fernández, J., Gestal, A., Holley, M., Borthagaray, G., Stokes, H. “Urinary Tract Infections in a South American Population: Dynamic Spread of Class 1 Integrons and Multidrug Resistance by Homologous and Site-specific Recombination.” Journal of Clinical Microbiology 2008; 46:3417–3425.
151 Krauland, M., Marsh, J., Paterson, D., Harrison, L. “Integron-Mediated Multidrug Resistance in a Global Collection of Nontyphoidal Salmonella enterica Isolates.” Emerging Infectious Diseases 2009; 15:388–396.
152 Coburn, P., Baghdayan, A., Dolan, G., Shankar, N. “Horizontal Transfer of Virulence Genes Encoded on the Enterococcus faecalis Pathogenicity Island.” Molecular Microbiology 2006; 63:530–544.
153 Lujan, S.A G.L, Ragonese, H., Matson, S.W., Redinbo, M.R. “Disrupting Antibiotic Resistance propagation by Inhibiting the Conjugative DNA Relaxase.” Proceedings of the National Academy of Sciences U.S.A. 2007; 104:12282–12287.
154 Wang, X., Zhao, X., Malik, M., Drlica, K. “Contribution of Reactive Oxygen Species to Pathways of Quinolone-Mediated Bacterial Cell Death.” Journal of Antimicrobial Chemotherapy 2010; 65:520-524.
Chapter 7
155 Reichman, L.B., Tanne, J. Timebomb: The Global Epidemic of Multi-Drug-Resistant Tuberculosis. New York: McGraw-Hill, 2002:240.
156 Bearden, D., Allen, G. “Impact of Antimicrobial Control Programs on Patient Outcomes.” Disease Management and Health Outcomes 2003; 11:723–736.
157 Escombe, A., Moore, D., Gilman, R., Pan, W., Navincopa, M., Ticona, E., Martínez, C., Caviedes, L., Sheen, P., Gonzalez, A., Noakes, C., Friedland, J., Evans, C. “The Infectiousness of Tuberculosis Patients Coinfected with HIV.” Plos Medicine 2008; 5:e188.
158 McAdam, J., Bucher, S., Brickner, P., Vincent, R., Lascher, S. “Latent Tuberculosis and Active Tuberculosis Disease Rates Among the Homeless, New York, New York, USA, 1992–2006.” Emerging Infectious Diseases 2009; 15:1109–1111.
159 Xu, C., Kreiswirth, B.N., Sreevatsan, S., Musser, J.M., Drlica, K. “Fluoroquinolone Resistance Associated with Specific Gyrase Mutations in Clinical isolates of Multidrug Resistant Mycobacterium tuberculosis.” Journal of Infectious Diseases 1996; 174:1127–1130.
160 Frieden, T., Fujiwara, P., Washko, R., Hamburg, M. “Tuberculosis in New York City—Turning the Tide.” New England Journal of Medicine 1995; 333:229–233.
161 White, V., Moore-Gillon, J. “Resource Implications of Patients with Multidrug Resistant Tuberculosis.” Thorax 2000; 55:962–963.
162 Dewan, R., Sosnovskaja, A., Thomsen, V., Cicenaite, J., Laseson, K., Johansen, I., Davidaviciene, E., Wells, C., “High Prevalence of Drug-Resistant Tuberculosis, Republic of Lithuania, 2002.” International Journal of Tuberculosis and Lung Disease 2005; 9:170–174.
163 Badiaga, S., Raoult, D., Brouqui, P. “Preventing and Controlling Emerging and Reemerging transmissible Diseases in the Homeless.” Emerging Infectious Diseases 2008; 14:1353–1359.
164 Tellier, R. “Review of Aerosol Transmission of Influenza A Virus.” Emerging Infectious Diseases 2006; 12:1657–1662.
165 Suzita, R., Abdulamir, A., Bakar, F., Son R. “A Mini Review: Cholera Outbreak via Shellfish.” American Journal of Infectious Disease 2009; 5:40–47.
166 Sagel, U., Schulte, B., Heeg, P., Borgmann, S. “Vancomycin-Resistant Enterococci Outbreak, Germany, and Calculation of Outbreak Start.” Emerging Infectious Diseases 2008; 14:317–319.
167 Whittington, A., Whitlow, G., Hewson, D., Thomas, C., Brett, S. “Bacterial Contamination of Stethoscopes on the Intensive Care Unit.” Anaesthesia 2009; 64:620–624.
168 Zinderman, C., Conner, B., Malakooti, M., LaMar, J., Armstrong, A., Bohnker, B. “Community-Acquired Methicillin-Resistant Staphylococcus aureus Among Military Recruits.” Emerging Infectious Diseases 2004; 10:941–944.
169 Kazakova, S., Hageman, J., Matava, M., Srinivasan, A., Phelan, L., Garfinkel, B., Boo, T., McAllister, S., Anderson, J., Jensen, B., Dodson, D., Lonsway, D., McDougal, L., Arduino, M., Fraser, V., Killgore, G., Tenover, F., Cody, S., Jernigan, D. “A Clone of Methicillin-Resistant Staphylococcus aureus Among Professional Football Players.” New England Journal of Medicine 2005; 352:468–475.
170 Huijsdens, X., van Lier, A., van Kregten, E., Verhoef, L., van Santen-Verheuvel, M., Spalburg, E., Wannet, W. “Methicillin-Resistant Staphylococcus aureus in Dutch Soccer Team.” Emerging Infectious Diseases 2006; 12:1584–1586.
171 Garza, D., Sungar, G., Johnston, T., Rolston, B., Ferguson, J., Matheson, G. “Ineffectiveness of Surveillance to Control Community-Acquired Methicillin-Resistant Staphylococcus aureus in a Professional Football Team.” Clinical Journal of Sports Medicine 2009; 19:498–501.
172 Freedman, D.O. “Clinical Practice: Malaria Prevention in Short-Term Travelers.” New England Journal of Medicine 2008; 359:603–612.
173 Bechah, Y., Capo, C., Mege, J., Raoult, D. “Epidemic Typhus.” Lancet Infect Diseases 2008; 8:417–426.
174 Reisen, W., Takahashi, R., Carroll, B., Quiring, R. “Delinquent Mortgages, Neglected Swimming Pools, and West Nile Virus, California.” Emerging Infectious Diseases 2008; 14:1747–1749.
175 Goodman, R., Buehler, J. “Delinquent Mortgages, Neglected Swimming Pools, and West Nile Virus, California.” Emerging Infectious Diseases 2009; 15:508.
176 Reisen, W., Takahashi, R., Carroll, B., Quiring, R. “Delinquent Mortgages, Neglected Swimming Pools, and West Nile Virus, California.” Emerging Infectious Diseases 2009; 15:508–509.
177 Groopman, J. “Superbugs.” The New Yorker, August 11, 2008:46–55.
178 Quale, J. “Global Spread of Carbapenemase-Producing Klebsiella pneumoniae.” Microbe 2008; 3:516–520.
179 Clock, S., Cohen, B., Behta, M., Ross, B., Larson, E. “Contact Precautions for Multidrug-Resistant Organisms: Current Recommendations and Actual Practice.” American Journal of Infection Control 2010; 38:105–111.
180 Larson, E. “Hygiene of the Skin: When Is Clean Too Clean.” Emerging Infectious Diseases 2001; 7:225–230.
Chapter 8
181 Hall, G., Yohannes, K., Raupach, J., Becker, N., Kirk, M. “Estimating Community Incidence of Salmonella, Campylobacter, and Shiga Toxin-Producing Escherichia coli Infections, Australia.” Emerging Infectious Diseases 2008; 14:1601–1609.
182 Masterton, R. “The Importance and Future of Antimicrobial Surveillance Studies.” Clinical Infectious Diseases 2008; 47:S21–S31.
183 Tyagi, S., Bratu, D., Kramer, F. “Multicolor Molecular Beacons for Allele Discrimination.” Nature Biotechnology 1998; 16:49–53.
184 El-Hajj, H., Marras, S., Tyagi, S., Shashkina, E., Kamboj, M., Kiehn, T., Glickman, M., Kramerj, F., Alland, A. “Use of Sloppy Molecular Beacon Probes for Identification of Mycobacterial Species.” Journal of Clinical Microbiology 2009; 47:1190–1198.
185 Karlowsky, J., Sahm, D. “Antibiotic Resistance—Is Resistance Detected by Surveillance Relevant to Predicting Resistance in the Clinical Setting?” Current Opinion in Pharmacology 2002; 2:487–492.
186 Morris, A., Masterton, R. “Antibiotic Resistance Surveillance: Action for International Studies.” Journal of Antimicrobial Chemotherapy 2002; 49:7–10.
187 Nelson, J., Chiller, T., Powers, J., Angulo, F. “Fluoroquinolone-Resistant Campylobacter Species and the Withdrawal of Fluoroquinolones from Use in Poultry: A Public Health Success Story.” Clinical Infectious Diseases 2007; 44:977–980.
188 Willems, R., Top, J., vanSanten, M., Robinson, D., Coque, T., Baquero, F., Grundmann, H., Bonten, M., “Global Spread of Vancomycin-Resistant Enterococcus faecium from Distinct Nosocomial Genetic Complex.” Emerging Infectious Diseases 2005; 11:821–828.
Chapter 10
189 Seppala, H., Klaukka, T., Vuopio-Varkila, J., Maotiala, A., Helenius, H., Lager, K. “The Effect of Changes in the Consumption of Macrolide Antibiotics on Erythromycin Resistance in Group A Streptococci in Finland.” New England Journal of Medicine 1997; 337:441–446.
190 Kristinsson, K. “Effect of Antimicrobial Use and Other Risk Factors on Antimicrobial Resistance in Pneumococci.” Microbial Drug Resistance 1997; 3:117–123.
191 Deschepper, R. VSR, Haaijer-Ruskamp, F.M. “Cross-Cultural Differences in Lay Attitudes and Utilisation of Antibiotics in a Belgian and a Dutch City.” Patient Education and Counseling 2002; 48:161–169.
192 Davey, P., Brown, E., Fenelon, L., Finch, R., Gould, I., Holmes, A., Ramsay, C., Taylor, E., Wiffen, P., Wilcox, M. “Systematic Review of Antimicrobial Drug Prescribing in Hospitals.” Emerging Infectious Diseases 2006; 12:211–216.
193 Harbarth, S., Albrich, W., Brun-Buisson, C. “Outpatient Antibiotic Use and Prevalence of Antibiotic-Resistant Pneumococci in France and Germany: a Sociocultural Perspective.” Emerging Infectious Diseases 2002; 8:1460–1467.
194 Mathema, B., Cross, E., Dun, E., Park, S., Dedell, J., Slade, B., Williams, M., Riley, L., Chaturvedi, V., Perlin, D.S. “Prevalence of Vaginal Colonization by Drug-Resistant Candida Species in College-Age Women with Previous Exposure to Over-the-Counter Azole Antifungals.” Clinical Infectious Diseases 2001; 33:e23–e27.
195 Phillips, I., Casewell, M., Cox, T., DeGroot, B., Friis, C., Jones, R., Nightingale, C., Preston, R., Waddell, J. “Does the Use of Antibiotics in Food Animals Pose a Risk to Human Health? A Critical Review of Published Data.” Journal of Antimicrobial Chemotherapy 2004; 53:28–52.
196 Castanon, J. “History of the Use of Antibiotic as Growth Promoters in European Poultry Feeds.” Poultry Science 2007; 86:2466–2471.
197 Anonymous. “Avoiding Antibiotic Resistance: Denmark’s Ban on Growth Promoting Antibiotics in Food Animals.” The PEW Charitable Trusts, 2009.
198 Baquero, F., Martinex, J.-L., Canton, R. “Antibiotics and Antibiotic Resistance in Water Environments.” Current Opinion in Biotechnology 2008; 19:260–265.
199 Lin, A., Yu, T-H, Lin, C-F. “Pharmaceutical Contamination in Residential, Industrial, and Agricultural Waste Streams: Risk to Aqueous Environments in Taiwan.” Chemosphere 2008; 74:131–141.
200 Duong, H., Pham, N., Nguyen, H., Hoang, T., Pham, H., Pham, V., Berg, M., Giger, W., Alder, A. “Occurrence, Fate and Antibiotic Resistance of Fluoroquinolone Antibacterials in Hospital Wastewaters in Hanoi, Vietnam.” Chemosphere 2008; 72:968–973.
201 Baquero, F., Martínez, J., Cantón. R. “Antibiotics and Antibiotic Resistance in Water Environments.” Current Opinion in Biotechnology 2008; 19:260–265.
202 Verweij, P., Mellado, E., Melchers, W. “Multiple-Triazole-Resistant Aspergillosis.” New England Journal of Medicine 2007; 356:1481–1483.
203 Enserink, M. “Farm Fungicides Linked to Resistance in a Human Pathogen.” Science 2009; 326:1173.
204 Stratton, C. “Dead Bugs Don’t Mutate: Susceptibility Issues in the Emergence of Bacterial Resistance.” Emerging Infectious Diseases 2003; 9:10–16.
205 Lipsitch, M., Levin, B. “The Population Dynamics of Antimicrobial Chemotherapy.” Antimicrobial Agents and Chemotherapy 1997; 41:363–373.
206 Gumbo, T., Louie, A., Deziel, M., Drusano, G.L. “Pharmacodynamic Evidence That Ciprofloxacin Failure Against Tuberculosis Is Not Due to Poor Microbial Kill but to Rapid Emergence of Resistance.” Antimicrobial Agents and Chemotherapy 2005; 49:3178–3181.
207 Tam, V., Louie, A., Fritsche, T., Deziel, M., Liu, W., Brown, D., Deshpande, L., Leary, R., Jones, R., Drusano, GT. “Impact of Drug-Exposure intensity and Duration of Therapy on the Emergence of Staphylococcus aureus Resistance to a Quinolone Antimicrobial.” Journal of Infectious Diseases 2007; 195:1818–1827.
208 Guillemot, D., Carbon, C., Balkau, B., Geslin, P., Lecoeur, H., Vauzelle-Kervroedan, F., Bouvenot, G., Eschwege, E. “Low Dosage and Long Treatment Duration of β-lactam: Risk Factors for Carriage of Penicillin-Resistant Streptococcus pneumoniae.” JAMA 1998; 279:365–370.
209 Dong, Y., Zhao, X., Domagala, J., Drlica, K. “Effect of Fluoroquinolone Concentration on Selection of Resistant Mutants of Mycobacterium bovis BCG and Staphylococcus aureus.” Antimicrobial Agents and Chemotherapy 1999; 43:1756–1758.
210 Firsov, A., Smirnova, M., Lubenko, I., Vostrov, S., Portnoy, Y., Zinner, S. “Testing the Mutant Selection Window Hypothesis with Staphylococcus aureus Exposed to Daptomycin and Vancomycin in an in vitro Dynamic Model.” Journal of Antimicrobial Chemotherapy 2006; 58:1185–1192.
211 Hansen, G., Metzler. K., Drlica, K., Blondeau, J.M. “Mutant Prevention Concentration for Gemifloxacin with Clinical Isolates of Streptococcus pneumoniae.” Antimicrobial Agents and Chemotherapy 2003; 47:440–441.
212 Jumbe, N., Louie, A., Leary, R., Liu, W., Deziel, M., Tam, V., Bachhawat, R., Freeman, C., Kahn, J., Bush, K., Dudley, M., Miller, M., Drusano, G. “Application of a Mathematical Model to Prevent in Vivo Amplification of Antibiotic-Resistant Bacterial Populations During Therapy.” Journal of Clinical Investigation 2003; 112:275–285.
213 Drlica, K. “The Mutant Selection Window and Antimicrobial Resistance.” Journal of Antimicrobial Chemotherapy 2003; 52:11–17.
214 Marcusson, L., Olofsson, S., Lindgren, P., Cars, O., Hughes, D. “Mutant Prevention Concentration of Ciprofloxacin for Urinary Tract Infection Isolates of Escherichia coli.” Journal of Antimicrobial Chemotherapy 2005; 55:938–943.
215 Drlica, K., Zhao, X., Blondeau, J., Hesje, C. “Low Correlation Between Minimal Inhibitory Concentration (MIC) and mutant Prevention Concentration (MPC).” Antimicrobial Agents and Chemotherapy 2006; 50:403–404.
216 Tam, V., Louie, A., Deziel, M., Liu, W., Drusano. G. “The Relationship Between Quinolone Exposures and Resistance Amplification Is Characterized by an Inverted U: A New Paradigm for Optimizing Pharmacodynamics to Counterselect Resistance.” Antimicrobial Agents and Chemotherapy 2007; 51:744–747.
217 Li, X., Zhao, X., Drlica, K. “Selection of Streptococcus pneumoniae Mutants Having Reduced Susceptibility to Levofloxacin and Moxifloxacin.” Antimicrobial Agents and Chemotherapy 2002; 46:522–524.
218 Drlica, K., Zhao, X., Wang, J-Y, Malik, M., Lu, T., Park, S., Li, X., Perlin, D. “An Anti-Mutant Approach for Antimicrobial Use.” In: Fong, I., Drlica, K., eds. Antimicrobial Resistance and Implications for the 21st Century. New York City: Springer, 2008:371–400.
219 Bast, D., Low, D., Duncan, C., Kilburn, L., Mandell, L., Davidson, R., de Azavedo, J. “Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniae: Contributions of Type II Topoisomerase mutations and Efflux on Levels of Resistance.” Antimicrobial Agents and Chemotherapy 2000; 44:3049–3054.
220 Hedlin, P., Blondeau, J. “Comparative Minimal Inhibitory and Mutant Prevention Drug Concentrations of Four Fluoroquinolones Against Ocular Isolates of Haemophilus influenzae.” Eye and Contact Lens 2007; 33:161–164.
221 Fox, W., Elklard, G., Mitchison, D. “Studies on the Treatment of Tuberculosis Undertaken by the British Medical Research Council Tuberculosis Units, 1946–1986, with Relevant Subsequent Publications.” International Journal of Tuberculosis and Lung Disease 1999; 3:S231–S279.
222 Vernon, A., Burman, W., Benator, D., Khan, A., Bozeman, L. “Acquired Rifamycin Monoresistance in Patients with HIV-Related Tuberculosis Treated with Once-Weekly Rifapentine and Isoniazid.” The Lancet 1999; 353:1843–1847.
223 Ince, D., Zhang, X., Silver, L.C., Hooper, DC. “Dual Targeting of DNA gyrase and Topoisomerase IV: Target Interactions of Garenoxacin (BMS-284756, T-3811ME), a New Desfluoroquinolone.” Antimicrobial Agents and Chemotherapy 2002; 46:3370–3380.
224 Fisher, L.M., Heaton, V.J. “Dual Activity of Fluoroquinolones Against Streptococcus pneumoniae.” Journal of Antimicrobial Chemotherapy 2003; 51:463–464.
225 Strahilevitz, J., Hooper, D.C. “Dual Targeting of Topoisomerase IV and Gyrase to Reduce Mutant Selection: Direct Testing of the Paradigm by Using WCK-1734, a New Fluoroquinolone, and Ciprofloxacin.” Antimicrobial Agents and Chemotherapy 2005; 49:1949–1956.
226 Robertson, G., Bonventre, E., Doyle, T., Du, Q., Duncan, L., Morris, T., Roche, E., Yan, D., Lynch, A. “In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus.” Antimicrobial Agents and Chemotherapy 2008; 52:2313–2323.
227 Robertson, G., Bonventre, E., Doyle, T., Du, Q., Duncan, L., Morris, T., Roche, E., Yan, D., Lynch, A. “In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Microbiology Profiling Studies with Staphylococci and Streptococci.” Antimicrobial Agents and Chemotherapy 2008; 52:2324–2334.
228 Gutierrez, D. “Tyson Foods Injects Chickens with Antibiotics Before They Hatch to Claim ‘Raised Without Antibiotics.’” Naturalnews.com, November 9, 2008.
Chapter 11
229 Barry, J., Viboud,C., Simonsen, L. “Cross-Protection between Successive Waves of the 1918–1919 Influenza Pandemic: Epidemiological Evidence from US Army Camps and from Britain.” Journal of Infectious Diseases 2008; 198:1427–1434.
230 Brammer, L., Epperson, S., Blanton, L., Dhara, R., Wallis, T., Finelli, L., Fiore, A., Gubavera, L., Bresee, J., Klimov, A., Cox, N., Doshi, S. “Update: Influenza Activity—United States,” September 28—November 29, 2008. MMWR 2008; 57:1329–1332.
231 Lackenby, A., Thompson, C., Democratis, J. “The Potential Impact of Neuraminidase Inhibitor Resistant Influenza.” Current Opinion in Infectious Diseases 2008; 12:626–638.
232 Hill, A., Guralnick, R., Wilson, M., Habib, F., Janies, D. “Evolution of Drug Resistance in Multiple Distinct Lineages of H5N1 Avian Influenza Infection.” Genetics and Evolution 2009; 9:169–178.
233 Reece, P. “Neuraminidase Inhibitor Resistance in Influenza Viruses.” Journal of Medical Virology 2007; 79:1577–1586.
234 Hauge, S., Dudman, S., Borgen, K., Lackenby, A., Hungnes, O. “Oseltamivir-Resistant Influenza Viruses A (H1N1), Norway, 2007–08.” Emerging Infectious Diseases 2009; 15:155–162.
235 Meijer, A., Lackenby, A., Hungnes, O., Lina, B., van der Werf, S., Schweiger, B., Opp, M., Paget, J., van de Kassteele, J., Hay, A., Zambon, M., and European Influenza Surveillance Scheme. “Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season.” Emerging Infectious Diseases 2009; 15:552–560.
236 Cheng, P., To, A., Leung, T., Leung, P., Lee, C., Lim, W. “Oseltamivir- and Amantadine-Resistant Influenza Virus A (H1N1).” Emerging Infectious Diseases 2010; 16:155–156.
237 Taubenberger, J., Morens, D. “1918 Influenza: the Mother of All Pandemics.” Emerging Infectious Diseases 2006; 12:15–22.
238 Gupta, R., George, R., Nguyen van Tam, J. “Bacterial Pneumonia and Pandemic Influenza Planning.” Emerging Infectious Diseases 2008; 14:1187–1192.
239 Shoham, D. “Review: Molecular Evolution and the Feasibility of an Avian Influenza Virus Becoming a Pandemic Strain—a Conceptual Shift.” Virus Genes 2006; 33:127–132.
240 Vijaykrishna, D., Bahl, J., Riley, S., Duan, L., Zhang, J., Chen, H., Peiris, J., Smith, G., Guan, Y. “Evolutionary Dynamics and Emergence of Panzootic H5N1 Influenza Viruses.” PloS Pathogens 2008; 4:e1000161.
241 Nguyen, T.D., Nguyen, T.V., Vijaykrishna, D., Webster, R., Guan, Y., Peiris, J., Smith, G. “Multiple Sublineages of Influenza A Virus (H5N1), Vietnam, 2005–2007.” Emerging Infectious Diseases 2008; 14:632–636.
242 de Jong, M., Tran, T., Truong, H., Vo, M., Smith, G., Nguyen, V., Bach, V., Phan, T., Do, D., Guan, Y., Peiris, J., Tran, T., Farrar, J. “Oseltamivir Resistance During Treatment of Influenza A (H5N1) Infection.” New England Journal of Medicine 2005; 353:1729–1732.
243 Brundage, J.F., Shanks, G.D. “Deaths from Bacterial Pneumonia During 1918–19 Influenza Pandemic.” Emerging Infectious Diseases 2008; 14:1193–1199.
244 Klugman, K., Astley, C., Lipsitch, M. “Time from Illness Onset to Death, 1918 Influenza and Pneumococcal Pneumonia.” Emerging Infectious Diseases 2009; 15:346–347.
245 Doshi, P. “Popular and Scientific Attitudes Regarding Pandemic Influenza.” Emerging Infectious Diseases 2008; 14:1501–1502.
246 Ortiz, J.R., Kamimoto, L., Aubert, R., Yao, J., Shay, D., Bresee, J., Epstein, R., “Oseltamivir Prescribing in Pharmacy-Benefits Database, United States, 2004–2005.” Emerging Infectious Diseases 2008; 14:1280–1283.
247 Green, M., Nettey, H., Wirtz, R. “Determination of Oseltamivir Quality by Colorimetric and Liquid Chromatographic Methods.” Emerging Infectious Diseases 2008; 14:552–556.
Chapter 12
248 Sahm, D., Karlowsky, J., Kelly, L., Critchley, I., Jones, M., Thornsberry, C., Mauriz, Y., Kahn, J. “Need for Annual Surveillance of Antimicrobial Resistance in Streptococcus pneumoniae in the United States: 2-Year Longitudinal Analysis.” Antimicrobial Agents and Chemotherapy 2001; 45:1037–1042.
249 Karlowsky, J., Thornsberry, C., Jones, M., Evangelista, A., Critchley, I., Sahm, D. “Factors Associated with Relative Rates of Antimicrobial Resistance Among Streptococcus pneumoniae in the United States: Results from the TRUST Surveillance Program (1998–2002).” Clinical Infectious Diseases 2003; 36.
250 Valentine, V. “A Timeline of Andrew Speaker’s Infection.” www.npr.org./news/specials/tb/, June 6, 2007.
251 van der Sande, M., Teunis, P., Sabel, R. “Professional and Home-Made Face Masks Reduce Exposure to Respiratory Infections Among the General Population.” PLoS ONE 2008; 3:e2618.
252 Casanova, L., Alfano-Sobsey, E., Rutala, W., Weber, D., Sobsey, M. “Virus Transfer from Personal Protective Equipment to Healthcare Employees’ Skin and Clothing.” Emerging Infectious Diseases 2008; 14:1291–1293.
253 Casanova, L., Alfano-Sobsey, E., Rutala, W., Weber, D., Sobsey, M. “Virus Transfer from Personal Protective Equipment to Healthcare Employees’ Skin and Clothing.” Emerging Infectious Diseases 2008; 14:1291–1293.
254 Bayard, V., Kitsutani, P., Barria, E., Ruedas, L., Tinnin, D., Muñoz, C., de Mosca, I., Guerrero, G., Kant, R., Garcia, A., Caceres, L., Gracio, F., Quiroz, E., de Castillo, Z., Armien, B., Libel, M., Mills, J. “Outbreak of Hantavirus Pulmonary Syndrome, Los Santos, Panama, 1999–2000.” Emerging Infectious Diseases 2004; 10:1635–1642.
255 Martinez, V., Bellomo, C., San-Juan, J., Pinna, D., Forlenza, R., Elder, M., Padula, P. “Person-to-Person Transmission of Andes Virus.” Emerging Infectious Diseases 2005; 11:1848–1853.
256 Zhang, Y., Dong, X., Li, X., Ma, C., Xiong, H., Yan, G., Gao, N., Jiang, D., Li, M., Li, L., Zou, Y., Plyusnin, A. “Seoul Virus and Hantavirus Disease, Shenyang, People’s Republic of China.” Emerging Infectious Diseases 2009; 15:200–206.
257 Bearden, D., Allen, G., Christensen, J. “Comparative in Vitro Activities of Topical Wound Care Products Against Community-Associated Methicillin-Resistant Staphylococcus aureus.” Journal of Antimicrobial Chemotherapy 2008; 62:769–772.
258 Huijsdens, X., Janssen, M., Renders, N., Leenders, A., van Wijk, P., van Santen-Verheuvel, M., van Driel, J., Morroy, G. “Methicillin-Resistant Staphylococcus aureus in a Beauty Salon, the Netherlands.” Emerging Infectious Diseases 2008; 14:1797–1799.
259 Weese, J., Archambault, M., Willey, B., Hearn, P., Kreiswirth, B., Said-Salim, B., McGeer, A., Likhoshvay, Y., Prescott, J., Low, D. “Methicillin-Resistant Staphylococcus aureus in Horses and Horse Personnel, 2000–2002.” Emerging Infectious Diseases 2005; 11:430–435.
260 Baptiste, K., Williams, K., Willams, N., Wattret, A., Clegg, P., Dawson, S., Corkill, J., O’Neill, T., Hart, C. “Methicillin-Resistant Staphylococci in Companion Animals.” Emerging Infectious Diseases 2005; 11:1942–1944.
261 Lewis, H.C., Mølbak, K., Reese, C., Aarestrup, F., Selchau, M., Sørum, M., Skov, R. “Pigs as Source of Methicillin-Resistant Staphylococcus aureus CC398 Infections in Humans, Denmark.” Emerging Infectious Diseases 2008; 14:1383–1389.
262 van Loo, I., Diederen, B., Savelkoul, P., Woudenberg, J., Roosendaal, R., van Belkum, A., Lemmens den Toom, N., Verhulst, C., van Keulen, P., Kluytmans, J. “Methicillin-Resistant Staphylococcus aureus in meat Products, the Netherlands.” Emerging Infectious Diseases 2007; 13:1753–1755.
263 Persoons, D., VanHoorebeke, S., Hermans, K., Butaye, P., de Kruif, A., Haesebrouck, F., Dewulf, J. “Methicillin-Resistant Staphylococcus aureus in Poultry.” Emerging Infectious Diseases 2009; 15:452–453.
264 David, M., Mennella, C., Mansour, M., Boyle-Vavra, S., Daum, R. “Predominance of Methicillin-Resistant Staphylococcus aureus Among Pathogens Causing Skin and Soft Tissue Infections in a Large Urban Jail: Risk Factors and Recurrence Rates.” Journal of Clinical Microbiology 2008; 46:3222–3227.
265 Diep, B., Chambers, H., Graber, C., Szumowski, J., Miller, L., Han, L., Chen, J., Lin, F., Lin, J., Phan, T., Carleton, H., McDougal, L., Tenover, F., Cohen, D., Mayer, K., Sensabaugh, G., Perdreau-Remington, F. “Emergence of Multidrug-Resistant, Community-Associated, Methicillin-Resistant Staphylococcus aureus Clone USA300 in Men Who Have Sex with Men.” Annals of Internal Medicine 2008; 148:249–257.
266 Matsumoto, T., Muratani, T., Takahashi, K., Ikuyama, T., Yokoo, D., Ando, Y., Sato, Y., Kurashima, M., Shimokawa, H., Yanai, S. “Multiple Doses of Cefodizime Are Necessary for the Treatment of Neisseria gonorrhoeae Pharyngeal Infection.” Journal of Infection and Chemotherapy 2008; 12:145–147.
267 Workowski, K., Berman, S., Douglas, J. “Emerging Antimicrobial Resistance in Neisseria gonorrhoeae: Urgent Need to Strengthen Prevention Strategies. Annals of Internal Medicine 2008; 149:363–364.
268 Matsumoto, T., Muratani, T., Takahashi, K., Ikuyama, T., Yokoo, D., Ando, Y., Sato, Y., Kurashima, M., Shimokawa, H., Yanai, S. “Multiple Doses of Cefodizime Are Necessary for the Treatment of Neisseria gonorrhoeae Pharyngeal Infection.” Journal of Infection and Chemotherapy 2006; 12:145–147.
269 Allen, G., Hankins, C. “Evaluation of the Mutant Selection Window for Fluoroquinolones Against Neisseria gonorrhoeae.” Journal of Antimicrobial Chemotherapy 2009; 64:359–363.
270 Stäger, K., Legros, F., Krause, G., Low, N., Bradley, D., Desai, M., Graf, S., D’Amato, S., Mizuno, Y., Janzon, R., Petersen, E., Kester, J., Steffen, R., Schlagenhauf, P. “Imported Malaria in Children in Industrialized Countries, 1992–2002.” Emerging Infectious Diseases 2009; 15:185–191.
271 Askling, H., Nilsson, J., Tegnell, A., Janzon, R., Ekdahl, K. “Malaria Risk in Travelers.” Emerging Infectious Diseases 2005; 11:436–441.
272 Mason, M. “Quality of Malaria Pills in Africa Raises Resistance Fears.” Miami Herald Tribune International Edition. Miami, FL, February 9, 2010:8A.
273 Mumcuoglu, K., Hemingway, J., Miller, J., Ioffe-Uspensky, I., Klaus, S., Ben-Ishai, F., Galun, R. “Permethrin Resistance in the Head Louse Pediculus Capitis from Israel.” Medical and Veterinary Entomology 1995; 9:427–432.
274 Adak, G., Meakins, S., Yip, H., Lopman, B.A., O’Brien, S.J. “Disease Risks from Foods, England and Wales, 1996–2000.” Emerging Infectious Diseases 2005; 11:365–372.
275 Mead, P., Slutsker, L., Dietz, V., McCaig, L., Bresee, J., Shapiro, C., Griffin, P., Tauxe, R. “Food-Related Illness and Death in the United States.” Emerging Infectious Diseases 1999; 5:607–625.
276 Manges, A., Johnson, J., Foxman, B., O’Bryan, T., Fullerton, K., Riley, L. “Widespread Distribution of Urinary Tract Infections Caused by a Multidrug-Resistant Escherichia coli Clonal Group.” New England Journal of Medicine 2001; 345:1007–1013.
277 Johnson, J., McCabe, J., White, D., Johnston, B., Kuskowski, M., McDermott, P. “Molecular Analysis of Escherichia coli from Retail Meats (2002–2004) from the United States National Antimicrobial Resistance Monitoring System.” Clinical Infectious Diseases 2009; 49:195–201.
278 Rabatsky-Ehr, T., Whichard, J., Rossiter, S., Holland, B., Stamey, K., Headrick, M., Barrett, T., Angulo, F. and the NARMS Working Group. “Multidrug-Resistant Strains of Salmonella enterica Typhimurium, United States, 1997–1998.” Emerging Infectious Diseases 2004; 10:795–801.
279 Ryan, C., Nickels, M., Hargrett-Bean, N., Potter, M., Endo, T., Mayer, L., Langkop, C., Gibson, C., McDonald, R., Kenney, R. “Massive Outbreak of Antimicrobial-Resistant Salmonellosis Traced to Pasteurized Milk.” JAMA 1987; 258:3269–3274.
280 Olsen, S., Ying, M., Davis M., Deasy, M., Holland, B., Iampietro, L., Baysinger, C., Sassano, F., Polk, L., Gormley, B., Hung, M., Pilot, K., Orsini, M., Van Duyne, S., Rankin, S., Genese, C., Bresnitz, E., Smucker, J., Moll, M., Sobel J. “Multidrug-Resistant Salmonella typhimurium Infection from Milk Contaminated after Pasteurization.” Emerging Infectious Diseases 2004; 10:932–935.
281 Wedel, S., Bender, J., Leano, F., Boxrud, D., Hedberg, C., Smith, K. “Antimicrobial-Drug Susceptibility of Human and Animal Salmonella typhimurium, Minnesota, 1997–2003.” Emerging Infectious Diseases 2005; 11:1899–1906.
282 Fey, P., Safranek, T., Rupp, M., Dunne, E., Ribot, E., Iwen, P., Bradford, P., Angulo, F., Hinrichs, S. “Ceftriaxone-Resistant Salmonella Infection Acquired by a Child from Cattle.” New England Journal of Medicine 2000; 342:1242–1249.
283 Helms, M., Vastrup, P., Gerner-Smidt, P., Mølbak, K. “Excess Mortality Associated with Antimicrobial Drug-Resistant Salmonella typhimurium.” Emerging Infectious Diseases 2002; 8:490–495.
284 Molbak, K. “Human Health Consequences of Antimicrobial Drug-Resistant Salmonella and Other Foodborne Pathogens.” Clinical Infectious Diseases 2005; 41:1613–1620.
285 Nichols, G. “Fly Transmission of Campylobacter.” Emerging Infectious Diseases 2005; 11:361–364.
286 Hald, B., Sommer, H., Skovgård, H. “Use of Fly Screens to Reduce Campylobacter spp. Introduction in Broiler Houses.” Emerging Infectious Diseases 2007; 13:1951–1953.
287 Keen, J.E., Wittum, T., Dunn, J., Bono, J., Durso, L. “Shiga-Toxigenic Escherichia coli O157 in Agricultural Fair Livestock, United States.” Emerging Infectious Diseases 2006; 12:780–786.
288 Hsueh, P., Teng, L., Tseng, S, Chang, C., Wan, J., Yan, J., Lee, C., Chuang, Y., Huang, W., Yang, D., Shyr, J., Yu, K., Wang, L., Lu, J., Ko, W., Wu, J., Chang, F. “Ciprofloxacin-Resistant Salmonella enterica Typhimurium and Choleraesuis from Pigs to Humans, Taiwan.” Emerging Infectious Diseases 2004; 10:60–68.
289 Hald, B., Skovgård, H., Bang, D., Pedersen, K., Dybdahl, J., Jespersen, J., Madsen, M. “Flies and Campylobacter Infection of Broiler Flocks.” Emerging Infectious Diseases 2004; 10:1490–1492.
290 Riedner, G., Rusizoka, M., Todd, J., Maboko, L., Hoelscher, M., Mmbando, E., Samky, E., Lyamuya, E., Mabey, D., Grosskurth, H., Hayes, R. “Single-Dose Azithromycin Versus Penicillin G Benzathine for the Treatment of Early Syphilis.” New England Journal of Medicine 2005; 353:1236–44.
291 Katz, K., Klausner, J. “Azithromycin Resistance in Treponema pallidum.” Current Opinion in Infectious Diseases 2008; 21:83–91.
292 Walker, P., Reynolds, M., Ashbee, H., Brown, C., Evans, E. “Vaginal Yeasts in the Era of ‘Over the Counter’ Antifungals.” Sexually Transmitted Infections 2000; 76:437–438.
293 Sieradzki, K., Roberts, R., Haber, S., Tomasz, A. “The Development of Vancomycin Resistance in a Patient with Methicillin-Resistant Staphylococcus aureus Infection.” New England Journal of Medicine 1999; 340:517–523.
294 Aiello, A., Larson, E., Levy, S. “Consumer Antibacterial Soaps: Effective or Just Risky?” Clinical Infectious Diseases 2007; Suppl 2:S137–S147.
295 Shehab, N., Patel, P., Srinivasan, A., Budnitz, D. “Emergency Department Visits for Antibiotic-Associated Adverse Events.” Clinical Infectious Diseases 2008; 47:735–743.
296 Modena, S., Gollamudi, S., Friedenberg, F. “Continuation of Antibiotics is Associated with Failure of Metronidazole for Clostridium difficile-Associated Diarrhea.” Journal of Clinical Gastroenterology 2006; 40:49–54.
297 Ho, P.L., Tse, W.S., Tsang, K., Kwok, T., Ng, T., Cheng, V., Chan, R. “Risk Factors for Acquisition of Levofloxacin-Resistant Streptococcus pneumoniae: a Case-Control Study.” Clinical Infectious Diseases 2001; 32:701–707.
Afterword
298 Hammerum, A., Heuer, O., Emborg, H., Bagger-Skjøt, L., Jensen, V., Rogues, A., Skov, R., Agersø, Y., Brandt, C., Seyfarth, A., Muller, A., Hovgaard, K., Ajufo, J., Bager, F., Aarestrup, F., Frimodt-Møller, N., Wegener, H. “Danish Integrated Antimicrobial Resistance Monitoring and Research Program.” Emerging Infectious Diseases 2007; 13:1632–1639.
299 Lyte, M., Freestone, P. “Microbial Endocrinology Comes of Age.” Microbe 2009; 4:169–175.
Appendix B
300 Chang, D., Anderson, S., Wannemuehler, K., Engelthaler, D., Erhart, L., Sunenshine, R., Burwell, L., Park, B. “Testing for Coccidioidomycosis Among Patients with Community-Acquired Pneumonia.” Emerging Infectious Diseases 2008; 14:1053–1059.
301 Gauthier, G., Klein, B.S. “Insights into Fungal Morphogenesis and Immune Evasion.” Microbe 2008; 3:416–423.